Health Care · Biological Products, (No Diagnostic Substances)

HUMA Humacyte, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 181838270 filings
Russell 2000

HUMA at a glance

Humacyte, Inc. (HUMA, SEC CIK 1818382) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as October 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Humacyte, Inc. (HUMA) reported revenue of $2.0 million and a net loss of $40.8 million. Diluted EPS was -$0.26.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Humacyte, Inc. (HUMA) shares worth $10.9 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Jones Keith Anthony on September 14, 2026 of 10,000 shares at $0.56 per share.
  • In the last 90 days, HUMA insiders reported 1 open-market purchase ($6K) and 0 open-market sales ($0) on Form 4, a net purchase of $6K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.0M
10-K XBRL
Insiders · 90 days
1 buy · 0 sells
Net +$6K
13F holders
24 funds
$10.9M · −1 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $1.0M, up from $0.8M YoY, driven by Symvess product sales
  • Operating loss $23.5M vs $24.4M YoY, operating margin -2,288.3% vs -3,048.8%
  • Symvess product revenue $1.0M vs $0.7M, the only reported product line
  • Cash, equivalents and restricted cash $64.9M, up from $19.8M; operating cash use $62.1M vs $78.9M
  • Going-concern risk, insufficient liquidity beyond one year without higher Symvess sales or additional capital

Risk Factors

  • Cost-saving execution risk: May 2026 workforce reduction of approximately 45 employees
  • Nasdaq compliance risk: $1.00 bid-price requirement, with compliance deadline January 27, 2027
  • Delisting financing risk: Nasdaq removal could impair liquidity and capital-raising ability
  • Workforce disruption risk: severance costs could negatively impact cash flows
  • Talent retention risk: unplanned attrition could reduce productivity and organizational knowledge

AI summary of the HUMA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal Q3 2026 results for quarter ended September 30, 2026
  • Humacyte press release furnished as Exhibit 99.1, containing the detailed financial results

Item EX-99.1: Item EX-99.1

  • Symvess Q3 sales $1.0M, up 151% sequentially and 45% year over year, with ordering hospitals rising 44% to 49
  • October sales reached $0.8M, while management targets at least doubling Q3 sales in Q4, supporting commercial traction but raising execution expectations
Filed Sep 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Board additions target commercialization and global operations as Humacyte expands Symvess launch and prepares dialysis-access ATEV launch
  • Scott Coward adds public-company governance, M&A integration, legal, and compliance expertise through Audit Committee appointment

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expansion adds Scott Coward as Class I director through 2028 and Paul Kuznik as Class II director through 2029
  • Coward joins Audit Committee, adding public-company governance, legal, M&A and integration expertise

Item 7.01: Regulation FD Disclosure

  • Board appointments of Mr. Coward and Mr. Kuznik announced on September 28, 2026
  • New director additions may influence governance, oversight and strategic direction
Filed Aug 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal Q2 2026 results covered quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1 contains financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q2 sales rose to $0.4M from $0.1M, but $1.2M cost of goods sold reflects a $0.7M inventory reserve and unused capacity costs
  • V012 Phase 3 interim results showed 91 additional catheter-free days and infection rates of 6 versus 23 per 100 patient years

AI summaries of HUMA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for HUMA

Don't miss the next HUMA filing

  • Alerts as it files. A push when HUMA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut HUMA, by share count.
  • Ask anything. An AI agent that reads every HUMA filing and answers with sources.

HUMA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
COWARD D SCOTTAOct 6, 2026-
Kuznik Paul BrianAOct 6, 2026-
Jones Keith AnthonyBuySep 14, 2026$0.56
Jones Keith AnthonyBuyAug 20, 2026$0.69
Jones Keith AnthonyBuyAug 17, 2026$0.59
Windham-Bannister Susan RichardsAJun 11, 2026-
Constantino Michael T.AJun 11, 2026-
Brown Emery N.AJun 11, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$0$2.0M
Operating Income-$100.0M-$114.4M-$108.1M
Net Income-$110.8M-$148.7M-$40.8M
Op. Margin---5306.0%
Net Margin---2003.6%
Balance Sheet
Total Assets-$137.9M$116.4M
Equity$13.5M-$52.7M$3.1M
ROE-817.8%282.3%-1313.4%
Per Share
EPS-$-1.26$-0.26
Cash Flow
Operating CF-$73.3M-$98.1M-$105.0M
CapEx-$1.6M$884K

Source: XBRL data in Humacyte, Inc. (HUMA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate HUMA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
HUMA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$10.9M
Q2 202625$19.3M
Q1 202627$18.0M
Q4 202525$32.7M
Q3 202527$49.9M
Q2 202525$67.1M
Q1 202524$34.6M
Q4 202418$73.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 195 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

HUMA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 10, 2026Analysis-
10-QNov 10, 2026Analysis
4Oct 7, 2026--
4Oct 7, 2026--
8-KSep 28, 2026Analysis-
4Sep 15, 2026--
4Aug 21, 2026--
4Aug 19, 2026--
8-KAug 12, 2026Analysis-
10-QAug 12, 2026Analysis
8-KJul 31, 2026Analysis-
SC 13GJun 22, 2026-
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
8-KJun 11, 2026Analysis-
8-KJun 10, 2026Analysis

Related Health Care companies

All Health Care →

HUMA SEC filings: frequently asked questions

Are HUMA insiders buying or selling?

In the last 90 days, Humacyte, Inc. (HUMA) officers, directors and 10% owners reported 1 open-market purchase worth $5,620 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold HUMA stock?

As of September 30, 2026, the largest Humacyte, Inc. (HUMA) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($5.7 million), BlackRock ($2.4 million), Citadel Advisors LLC ($897,000), State Street Corp ($466,000), Vanguard Portfolio Management LLC ($398,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was HUMA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Humacyte, Inc. (HUMA) reported revenue of $2.0 million and a net loss of $40.8 million. Diluted EPS was -$0.26. The figures come from the XBRL data in the 10-K.

What did HUMA report in its latest 8-K?

Humacyte, Inc. (HUMA) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal Q3 2026 results for quarter ended September 30, 2026.

What are the latest HUMA SEC filings?

Humacyte, Inc. (HUMA) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on October 7, 2026.

What is HUMA's SEC CIK number?

Humacyte, Inc. (HUMA)'s SEC Central Index Key (CIK) is 1818382. EDGAR lists every HUMA filing under that number.

Ask anything about HUMA

The research agent reads HUMA's filings, financials, insider trades and 13F holders, then answers with sources.